Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology
Identifieur interne : 000C86 ( Pmc/Curation ); précédent : 000C85; suivant : 000C87Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology
Auteurs : Yoshikazu Honda-Okubo [Australie] ; Dale Barnard [États-Unis] ; Chun Hao Ong [Australie] ; Bi-Hung Peng [États-Unis] ; Chien-Te Kent Tseng [États-Unis] ; Nikolai Petrovsky [Australie]Source :
- Journal of Virology [ 0022-538X ] ; 2014.
Abstract
Although the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) epidemic was controlled by nonvaccine measures, coronaviruses remain a major threat to human health. The design of optimal coronavirus vaccines therefore remains a priority. Such vaccines present major challenges: coronavirus immunity often wanes rapidly, individuals needing to be protected include the elderly, and vaccines may exacerbate rather than prevent coronavirus lung immunopathology. To address these issues, we compared in a murine model a range of recombinant spike protein or inactivated whole-virus vaccine candidates alone or adjuvanted with either alum, CpG, or Advax, a new delta inulin-based polysaccharide adjuvant. While all vaccines protected against lethal infection, addition of adjuvant significantly increased serum neutralizing-antibody titers and reduced lung virus titers on day 3 postchallenge. Whereas unadjuvanted or alum-formulated vaccines were associated with significantly increased lung eosinophilic immunopathology on day 6 postchallenge, this was not seen in mice immunized with vaccines formulated with delta inulin adjuvant. Protection against eosinophilic immunopathology by vaccines containing delta inulin adjuvants correlated better with enhanced T-cell gamma interferon (IFN-γ) recall responses rather than reduced interleukin-4 (IL-4) responses, suggesting that immunopathology predominantly reflects an inadequate vaccine-induced Th1 response. This study highlights the critical importance for development of effective and safe coronavirus vaccines of selection of adjuvants based on the ability to induce durable IFN-γ responses.
Url:
DOI: 10.1128/JVI.02980-14
PubMed: 25520500
PubMed Central: 4337527
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000C86
Links to Exploration step
PMC:4337527Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology</title>
<author><name sortKey="Honda Okubo, Yoshikazu" sort="Honda Okubo, Yoshikazu" uniqKey="Honda Okubo Y" first="Yoshikazu" last="Honda-Okubo">Yoshikazu Honda-Okubo</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Vaxine Pty Ltd., Adelaide, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barnard, Dale" sort="Barnard, Dale" uniqKey="Barnard D" first="Dale" last="Barnard">Dale Barnard</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Institute for Antiviral Research, Utah State University, Logan, Utah, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Antiviral Research, Utah State University, Logan, Utah</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ong, Chun Hao" sort="Ong, Chun Hao" uniqKey="Ong C" first="Chun Hao" last="Ong">Chun Hao Ong</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Vaxine Pty Ltd., Adelaide, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Peng, Bi Hung" sort="Peng, Bi Hung" uniqKey="Peng B" first="Bi-Hung" last="Peng">Bi-Hung Peng</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">University of Texas Medical Branch, Galveston, Texas, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas Medical Branch, Galveston, Texas</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tseng, Chien Te Kent" sort="Tseng, Chien Te Kent" uniqKey="Tseng C" first="Chien-Te Kent" last="Tseng">Chien-Te Kent Tseng</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">University of Texas Medical Branch, Galveston, Texas, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas Medical Branch, Galveston, Texas</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Petrovsky, Nikolai" sort="Petrovsky, Nikolai" uniqKey="Petrovsky N" first="Nikolai" last="Petrovsky">Nikolai Petrovsky</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Vaxine Pty Ltd., Adelaide, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Diabetes and Endocrinology, Flinders University, Adelaide, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Diabetes and Endocrinology, Flinders University, Adelaide</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25520500</idno>
<idno type="pmc">4337527</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337527</idno>
<idno type="RBID">PMC:4337527</idno>
<idno type="doi">10.1128/JVI.02980-14</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000C86</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000C86</idno>
<idno type="wicri:Area/Pmc/Curation">000C86</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000C86</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology</title>
<author><name sortKey="Honda Okubo, Yoshikazu" sort="Honda Okubo, Yoshikazu" uniqKey="Honda Okubo Y" first="Yoshikazu" last="Honda-Okubo">Yoshikazu Honda-Okubo</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Vaxine Pty Ltd., Adelaide, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barnard, Dale" sort="Barnard, Dale" uniqKey="Barnard D" first="Dale" last="Barnard">Dale Barnard</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Institute for Antiviral Research, Utah State University, Logan, Utah, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Antiviral Research, Utah State University, Logan, Utah</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ong, Chun Hao" sort="Ong, Chun Hao" uniqKey="Ong C" first="Chun Hao" last="Ong">Chun Hao Ong</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Vaxine Pty Ltd., Adelaide, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Peng, Bi Hung" sort="Peng, Bi Hung" uniqKey="Peng B" first="Bi-Hung" last="Peng">Bi-Hung Peng</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">University of Texas Medical Branch, Galveston, Texas, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas Medical Branch, Galveston, Texas</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Tseng, Chien Te Kent" sort="Tseng, Chien Te Kent" uniqKey="Tseng C" first="Chien-Te Kent" last="Tseng">Chien-Te Kent Tseng</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">University of Texas Medical Branch, Galveston, Texas, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Texas Medical Branch, Galveston, Texas</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Petrovsky, Nikolai" sort="Petrovsky, Nikolai" uniqKey="Petrovsky N" first="Nikolai" last="Petrovsky">Nikolai Petrovsky</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Vaxine Pty Ltd., Adelaide, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaxine Pty Ltd., Adelaide</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><nlm:aff id="aff4">Department of Diabetes and Endocrinology, Flinders University, Adelaide, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Diabetes and Endocrinology, Flinders University, Adelaide</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Virology</title>
<idno type="ISSN">0022-538X</idno>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>ABSTRACT</title>
<p>Although the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) epidemic was controlled by nonvaccine measures, coronaviruses remain a major threat to human health. The design of optimal coronavirus vaccines therefore remains a priority. Such vaccines present major challenges: coronavirus immunity often wanes rapidly, individuals needing to be protected include the elderly, and vaccines may exacerbate rather than prevent coronavirus lung immunopathology. To address these issues, we compared in a murine model a range of recombinant spike protein or inactivated whole-virus vaccine candidates alone or adjuvanted with either alum, CpG, or Advax, a new delta inulin-based polysaccharide adjuvant. While all vaccines protected against lethal infection, addition of adjuvant significantly increased serum neutralizing-antibody titers and reduced lung virus titers on day 3 postchallenge. Whereas unadjuvanted or alum-formulated vaccines were associated with significantly increased lung eosinophilic immunopathology on day 6 postchallenge, this was not seen in mice immunized with vaccines formulated with delta inulin adjuvant. Protection against eosinophilic immunopathology by vaccines containing delta inulin adjuvants correlated better with enhanced T-cell gamma interferon (IFN-γ) recall responses rather than reduced interleukin-4 (IL-4) responses, suggesting that immunopathology predominantly reflects an inadequate vaccine-induced Th1 response. This study highlights the critical importance for development of effective and safe coronavirus vaccines of selection of adjuvants based on the ability to induce durable IFN-γ responses.</p>
<p><bold>IMPORTANCE</bold>
Coronaviruses such as SARS-CoV and Middle East respiratory syndrome-associated coronavirus (MERS-CoV) cause high case fatality rates and remain major human public health threats, creating a need for effective vaccines. While coronavirus antigens that induce protective neutralizing antibodies have been identified, coronavirus vaccines present a unique problem in that immunized individuals when infected by virus can develop lung eosinophilic pathology, a problem that is further exacerbated by the formulation of SARS-CoV vaccines with alum adjuvants. This study shows that formulation of SARS-CoV spike protein or inactivated whole-virus vaccines with novel delta inulin-based polysaccharide adjuvants enhances neutralizing-antibody titers and protection against clinical disease but at the same time also protects against development of lung eosinophilic immunopathology. It also shows that immunity achieved with delta inulin adjuvants is long-lived, thereby overcoming the natural tendency for rapidly waning coronavirus immunity. Thus, delta inulin adjuvants may offer a unique ability to develop safer and more effective coronavirus vaccines.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Virol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Virol</journal-id>
<journal-id journal-id-type="hwp">jvi</journal-id>
<journal-id journal-id-type="pmc">jvi</journal-id>
<journal-id journal-id-type="publisher-id">JVI</journal-id>
<journal-title-group><journal-title>Journal of Virology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-538X</issn>
<issn pub-type="epub">1098-5514</issn>
<publisher><publisher-name>American Society for Microbiology</publisher-name>
<publisher-loc>1752 N St., N.W., Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">25520500</article-id>
<article-id pub-id-type="pmc">4337527</article-id>
<article-id pub-id-type="publisher-id">02980-14</article-id>
<article-id pub-id-type="doi">10.1128/JVI.02980-14</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Vaccines and Antiviral Agents</subject>
</subj-group>
</article-categories>
<title-group><article-title>Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology</article-title>
<alt-title alt-title-type="running-head">Delta Inulin-Adjuvanted SARS Vaccines</alt-title>
<alt-title alt-title-type="short-authors">Honda-Okubo et al.</alt-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Honda-Okubo</surname>
<given-names>Yoshikazu</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Barnard</surname>
<given-names>Dale</given-names>
</name>
<xref ref-type="aff" rid="aff2"><sup>b</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Ong</surname>
<given-names>Chun Hao</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Peng</surname>
<given-names>Bi-Hung</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Tseng</surname>
<given-names>Chien-Te Kent</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1580-5245</contrib-id>
<name><surname>Petrovsky</surname>
<given-names>Nikolai</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff4"><sup>d</sup>
</xref>
</contrib>
<aff id="aff1"><label>a</label>
Vaxine Pty Ltd., Adelaide, Australia</aff>
<aff id="aff2"><label>b</label>
Institute for Antiviral Research, Utah State University, Logan, Utah, USA</aff>
<aff id="aff3"><label>c</label>
University of Texas Medical Branch, Galveston, Texas, USA</aff>
<aff id="aff4"><label>d</label>
Department of Diabetes and Endocrinology, Flinders University, Adelaide, Australia</aff>
</contrib-group>
<contrib-group><contrib contrib-type="editor"><name><surname>Perlman</surname>
<given-names>S.</given-names>
</name>
<role>Editor</role>
</contrib>
</contrib-group>
<author-notes><corresp id="cor1">Address correspondence to Nikolai Petrovsky, <email>nikolai.petrovsky@flinders.edu.au</email>
.</corresp>
<fn fn-type="other"><p><bold>Citation</bold>
Honda-Okubo Y, Barnard D, Ong CH, Peng B-H, Tseng C-TK, Petrovsky N. 2015. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol 89:2995–3007. doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JVI.02980-14">10.1128/JVI.02980-14</ext-link>
.</p>
</fn>
</author-notes>
<pub-date pub-type="epub"><day>17</day>
<month>12</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="collection"><day>15</day>
<month>3</month>
<year>2015</year>
</pub-date>
<volume>89</volume>
<issue>6</issue>
<fpage>2995</fpage>
<lpage>3007</lpage>
<history><date date-type="received"><day>13</day>
<month>10</month>
<year>2014</year>
</date>
<date date-type="accepted"><day>5</day>
<month>12</month>
<year>2014</year>
</date>
</history>
<permissions><copyright-statement>Copyright © 2015, American Society for Microbiology. All Rights Reserved.</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>American Society for Microbiology</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="zjv00615002995.pdf"></self-uri>
<abstract><title>ABSTRACT</title>
<p>Although the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) epidemic was controlled by nonvaccine measures, coronaviruses remain a major threat to human health. The design of optimal coronavirus vaccines therefore remains a priority. Such vaccines present major challenges: coronavirus immunity often wanes rapidly, individuals needing to be protected include the elderly, and vaccines may exacerbate rather than prevent coronavirus lung immunopathology. To address these issues, we compared in a murine model a range of recombinant spike protein or inactivated whole-virus vaccine candidates alone or adjuvanted with either alum, CpG, or Advax, a new delta inulin-based polysaccharide adjuvant. While all vaccines protected against lethal infection, addition of adjuvant significantly increased serum neutralizing-antibody titers and reduced lung virus titers on day 3 postchallenge. Whereas unadjuvanted or alum-formulated vaccines were associated with significantly increased lung eosinophilic immunopathology on day 6 postchallenge, this was not seen in mice immunized with vaccines formulated with delta inulin adjuvant. Protection against eosinophilic immunopathology by vaccines containing delta inulin adjuvants correlated better with enhanced T-cell gamma interferon (IFN-γ) recall responses rather than reduced interleukin-4 (IL-4) responses, suggesting that immunopathology predominantly reflects an inadequate vaccine-induced Th1 response. This study highlights the critical importance for development of effective and safe coronavirus vaccines of selection of adjuvants based on the ability to induce durable IFN-γ responses.</p>
<p><bold>IMPORTANCE</bold>
Coronaviruses such as SARS-CoV and Middle East respiratory syndrome-associated coronavirus (MERS-CoV) cause high case fatality rates and remain major human public health threats, creating a need for effective vaccines. While coronavirus antigens that induce protective neutralizing antibodies have been identified, coronavirus vaccines present a unique problem in that immunized individuals when infected by virus can develop lung eosinophilic pathology, a problem that is further exacerbated by the formulation of SARS-CoV vaccines with alum adjuvants. This study shows that formulation of SARS-CoV spike protein or inactivated whole-virus vaccines with novel delta inulin-based polysaccharide adjuvants enhances neutralizing-antibody titers and protection against clinical disease but at the same time also protects against development of lung eosinophilic immunopathology. It also shows that immunity achieved with delta inulin adjuvants is long-lived, thereby overcoming the natural tendency for rapidly waning coronavirus immunity. Thus, delta inulin adjuvants may offer a unique ability to develop safer and more effective coronavirus vaccines.</p>
</abstract>
<counts><fig-count count="6"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="53"></ref-count>
<page-count count="13"></page-count>
<word-count count="9003"></word-count>
</counts>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000C86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Pmc |étape= Curation |type= RBID |clé= PMC:4337527 |texte= Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:25520500" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |